Many patients will recover vision back to the 20/20 level, however, patients will often report that vision in the affected eye is not quite as good as the normal eye even long after the fluid has resolved. Approximately 25% of patients develop a recurrent episode. There is also a subset of patients with significant retinal pigment epithelial abnormalities that are predisposed to attacks in both eyes, often simultaneously, and the prognosis in this group is much less optimistic, though with treatment many can maintain reading and driving vision.
In April 2017, Lucentis received FDA approval for use in all patients with diabetic retinopathy. Previously, Lucentis could be used in patients with diabetic retinopathy, only they also had diabetic macular edema. The Rise and Ride Clinical Trials demonstrated that not only does Lucentis help to improve macular edema, it also can reverse the progression of retinopathy in up to 38% of patients. Now all patients with diabetic retinopathy can receive this beneficial treatment when appropriate. Brown DM, et al; RISE and RIDE Research Group. Ophthalmology. 2013;120:2013-2022.